The company is paying China-based biotech LaNova Medicines $588 million for the same type of bispecific antibody drug that ...

Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, make and ...

Merck & Co. licensed an experimental cancer antibody from a closely held Chinese company in a deal worth $588 million upfront ...

(Reuters) -Merck has signed a licensing agreement worth up to $3.3 billion with Shanghai-based LaNova Medicines to develop, ...

Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...

Merck (MRK) stock will be in focus as company inks deal worth up to $3.3B to buy licensing rights to a cancer candidate ...

FRANKFURT, Nov 14 (Reuters) - Merck KGaA (MRCG.DE), opens new tab on Thursday reported a gain of 11.9% in adjusted quarterly ...

Merck reported third-quarter earnings growth above expectations, helped by lower spending and a positive performance in ...

The life-sciences and chemical group said it now expects 2024 net sales in the lower half of its previously expected range of ...

As the rollout of its recently launched pulmonary arterial hypertension (PAH) drug Winrevair ramps up, Merck is continuing ...

Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...

In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...